Literature DB >> 1650938

Treatment of retinal detachments in patients with the acquired immune deficiency syndrome.

J Orellana1, S A Teich, R M Lieberman, S Restrepo, R Peairs.   

Abstract

Thirty-nine eyes from 31 patients with retinal detachment due to cytomegalovirus (CMV) retinitis were treated by either laser photocoagulation (22 eyes), scleral buckle (9 eyes), pars plana vitrectomy (5 eyes), or no therapy (3 eyes). The success rates for photocoagulation (77.2%), scleral buckle (77.7%), and vitrectomy (with gas or oil, 80%) were similar. The median survival time was 95 days (range, of 7 to 280 days). The extent of detachment, the presence of active disease in either the periphery or the posterior pole, and overall health served to determine what type of therapy was best suited for each patient. Although silicone oil appears to be best for patients with a total retinal detachment and active disease, this small series suggests that conservative modes of therapy such as laser photocoagulation and scleral buckles can be used successfully to treat these patients if there is an absence of active retinitis.

Entities:  

Mesh:

Year:  1991        PMID: 1650938     DOI: 10.1016/s0161-6420(91)32217-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

Review 1.  The management of cytomegalovirus retinitis in AIDS.

Authors:  B Dhillon
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

2.  Ocular manifestations of HIV infection.

Authors:  D A Jabs
Journal:  Trans Am Ophthalmol Soc       Date:  1995

3.  Retinal detachments in patients with AIDS and CMV retinopathy: a role for laser photocoagulation.

Authors:  P McCluskey; J Grigg; T J Playfair
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

4.  Retinal detachment and herpesvirus retinitis in patients with AIDS.

Authors:  J G Dowler; H M Towler; S M Mitchell; R J Cooling; S L Lightman
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.